Literature DB >> 3987789

Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

M Eichelbaum, N M Woolhouse.   

Abstract

Sparteine oxidation, which exhibits genetic polymorphism in various Caucasian populations, was studied in 154 unrelated Ghanaian subjects. Mean total urinary recovery of sparteine and 2- and 5-dehydrosparteines (56.6 +/- 16.6% of the dose) was not different from Caucasians. In contrast to Caucasians, amongst whom 6.3 to 9% of the population are poor metabolizers (PM), no PM subject was observed in the Ghanaian population sample. The data appear to indicate allelic differences between Caucasians and Ghanaians in the gene encoding the synthesis of the P-450 isozyme involved in polymorphic sparteine oxidation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987789     DOI: 10.1007/bf00635712

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

Review 1.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.

Authors:  J R Idle; R L Smith
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

Review 2.  Multiple forms of inducible drug-metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity.

Authors:  D W Nebert
Journal:  Mol Cell Biochem       Date:  1979-09-28       Impact factor: 3.396

3.  Studies on microbial transformation. XXVI. Microbial oxidation of (-)-sparteine.

Authors:  K Furuya; K Aida; Y Koiso; S Okuda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1973-01       Impact factor: 1.645

4.  Multiple forms of cytochrome P450 in the microsomal monooxygenase system.

Authors:  V Ullrich; P Kremers
Journal:  Arch Toxicol       Date:  1977-12-30       Impact factor: 5.153

Review 5.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 6.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

10.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  19 in total

1.  Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics.

Authors:  T D Arias; L F Jorge; R Barrantes
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 3.  Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.

Authors:  P A De Smet; J R Brouwers
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

4.  Evidence for polymorphic oxidation of sparteine in Japanese subjects.

Authors:  T Ishizaki; M Eichelbaum; Y Horai; K Hashimoto; K Chiba; H J Dengler
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

5.  No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama.

Authors:  T D Arias; L F Jorge; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

Review 6.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

9.  Sparteine oxidation polymorphism: a family study.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

10.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Authors:  W E Evans; M V Relling; A Rahman; H L McLeod; E P Scott; J S Lin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.